These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7797782)

  • 21. MedWatch. On lookout for medical product problems.
    Ropp KL
    FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
    [No Abstract]   [Full Text] [Related]  

  • 22. MedWatch targets reporting of serious adverse events.
    VanAmringe M
    Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
    [No Abstract]   [Full Text] [Related]  

  • 23. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
    Kessler DA
    Gen Hosp Psychiatry; 1994 Mar; 16(2):96-101; discussion 102. PubMed ID: 8039699
    [No Abstract]   [Full Text] [Related]  

  • 24. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA
    Food Drug Law J; 2007; 62(3):513-28. PubMed ID: 17915393
    [No Abstract]   [Full Text] [Related]  

  • 25. MedWatch. FDA's 'heads up' on medical product safety.
    Henkel J
    FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
    [No Abstract]   [Full Text] [Related]  

  • 26. Postmarketing surveillance--lack of vigilance, lack of trust.
    Fontanarosa PB; Rennie D; DeAngelis CD
    JAMA; 2004 Dec; 292(21):2647-50. PubMed ID: 15572723
    [No Abstract]   [Full Text] [Related]  

  • 27. Serious adverse events in Norplant users related to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
    Chez RA
    Obstet Gynecol; 1995 Jul; 86(1):154-5. PubMed ID: 7784014
    [No Abstract]   [Full Text] [Related]  

  • 28. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems.
    Kessler DA
    JAMA; 1993 Jun; 269(21):2765-8. PubMed ID: 8492403
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse drug effects: new information about an old problem.
    Miller CA
    Geriatr Nurs; 2001; 22(6):336-7. PubMed ID: 11780009
    [No Abstract]   [Full Text] [Related]  

  • 30. Monitoring adverse drug events: the Food and Drug Administration MedWatch reporting system.
    Landow L
    Reg Anesth Pain Med; 1998; 23(6 Suppl 2):190-3. PubMed ID: 9845393
    [No Abstract]   [Full Text] [Related]  

  • 31. Prescription drugs, products liability, and preemption of tort litigation.
    DeAngelis CD; Fontanarosa PB
    JAMA; 2008 Oct; 300(16):1939-41. PubMed ID: 18940985
    [No Abstract]   [Full Text] [Related]  

  • 32. Serious adverse events in Norplant users reported to the Food and Drug Administration's MedWatch Spontaneous Reporting System.
    Sivin I
    Obstet Gynecol; 1995 Aug; 86(2):318-20. PubMed ID: 7617371
    [No Abstract]   [Full Text] [Related]  

  • 33. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 34. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 35. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
    Steenburg C
    Food Drug Law J; 2006; 61(2):295-383. PubMed ID: 16903034
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 37. FDA guidance document on monitoring delayed adverse events a good first start.
    Williams DA
    Mol Ther; 2005 Dec; 12(6):991-2. PubMed ID: 16271514
    [No Abstract]   [Full Text] [Related]  

  • 38. Avoiding the regulatory capture of the Food and Drug Administration.
    Egilman DS; Presler AH; Valentin CS
    Arch Intern Med; 2007 Apr; 167(7):732-3. PubMed ID: 17420438
    [No Abstract]   [Full Text] [Related]  

  • 39. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
    Mooghali M; Mohammad A; Wallach JD; Mitchell AP; Ross JS; Ramachandran R
    JAMA Netw Open; 2024 May; 7(5):e249233. PubMed ID: 38691363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.